BAP1 and miR-31 combination predicts outcome in epithelioid malignant pleural mesothelioma

被引：0
|
作者：
Pecci, F. [1 ]
Cantini, L. [2 ]
Cognigni, V. [1 ]
Murrone, A. [1 ]
Monaco, F. [3 ]
Rubini, C. [4 ]
Barbisan, F. [4 ]
Copparoni, C. [1 ]
Rinaldi, S. [1 ]
Fiordoliva, I. [1 ]
Paolo, M. Di Pietro [1 ]
Scarpelli, M. [4 ]
Tomasetti, M. [3 ]
Santarelli, L. [3 ]
Berardi, R. [1 ]
机构：
[1] Univ Politecn Marche, Azienda Osped Univ Osped Riuniti Umberto I, GM Lancisi, Clin Oncol,G Salesi, Ancona, Italy
[2] Univ Politecn Marche, Clin Oncol, Ancona, Italy
[3] Dipartimento Sci Clin & Mol, Med Lavoro, Ancona, Italy
[4] Univ Politecn Marche, Azienda Osped Univ Osped Riuniti Umberto I, Anat Patol, GM Lancisi,G Salesi, Ancona, Italy
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1448
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1905P
引用
收藏
页码：S1080 / S1080
页数：1
相关论文
共 50 条
  • [31] A Combination of BAP1, 5-HMC and MTAP Immunohistochemical Staining in Malignant Mesothelioma Effusions
    Shahi, Maryam
    Antic, Tatjana
    Fitzpatrick, Carrie
    Husain, Aliya
    Krausz, Thomas
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 420 - 420
  • [32] Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion
    Taylor, Steve
    Carpentieri, David
    Williams, James
    Acosta, Juan
    Southard, Richard
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2015, 37 (05) : e323 - e327
  • [33] BAP1, a tumor suppressor gene driving malignant mesothelioma
    Cheung, Mitchell
    Testa, Joseph R.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (03) : 270 - 278
  • [34] Somatic BAP1 and NF2 mutations in pleural malignant mesothelioma and their correlation with clinical phenotype
    Gennatas, S.
    Lu, S. K.
    Anbunathan, H.
    Popat, S.
    O'Brien, M.
    Lim, E.
    Fernandez, A. Montero
    Benepal, T.
    Nicholson, A. G.
    Lathrop, M.
    Moffatt, M.
    Cookson, W.
    Bowcock, A. M.
    LUNG CANCER, 2017, 103 : S25 - S26
  • [35] BAP1 loss in the diagnosis of malignant mesothelioma; review of a regional mesothelioma MDT
    Mcdill, H.
    Dipper, A.
    Bhatt, N.
    Clive, A.
    Maskell, N.
    Bibby, A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [36] BAP1 EXPRESSION AND TREATMENT OUTCOMES IN MALIGNANT PLEURAL MESOTHELIOMA IN A PROSPECTIVE UK BASED CLINICAL TRIAL
    Kumar, N.
    Kolluri, K.
    Al Rifai, D.
    Ishii, Y.
    Borg, E.
    Falzon, M.
    Nicholson, A.
    Janes, S.
    THORAX, 2017, 72 : A16 - A17
  • [37] A Combination of BAP1, 5-HMC and MTAP Immunohistochemical Staining in Malignant Mesothelioma Effusions
    Shahi, Maryam
    Antic, Tatjana
    Fitzpatrick, Carrie
    Husain, Aliya
    Krausz, Thomas
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 420 - 420
  • [38] Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
    Pulford, Emily
    Huilgol, Kalyani
    Moffat, David
    Henderson, Douglas W.
    Klebe, Sonja
    DISEASE MARKERS, 2017, 2017
  • [39] Impact of BAP1 mutational status on immunotherapy outcomes in advanced malignant pleural mesothelioma: A single institution experience
    Ogbue, Olisaemeka
    Unlu, Serhan
    Sorathia, Sharmeen
    Nanah, Abdel Rahman
    Abdeljaleel, Fatima
    Haddad, Abdo S.
    Daw, Hamed
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma
    Xu, Duo
    Gao, Yanyun
    Yang, Haitang
    Spils, Marc
    Marti, Thomas M.
    Losmanova, Tereza
    Su, Min
    Wang, Wenxiang
    Zhou, Qinghua
    Dorn, Patrick
    Shu, Yongqian
    Peng, Ren-Wang
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (05):
12345